Weekly Diclazuril to Prevent EPM in Horses: What the Research Really Shows

By Dr Duncan Houston

Equine protozoal myeloencephalitis, or EPM, remains one of the most important neurologic diseases of horses in North America. Most cases are caused by Sarcocystis neurona, and horses become infected by ingesting sporocysts in feed or water contaminated by opossum feces. Exposure is common, but clinical disease is much less common, which is part of what makes prevention difficult to study. (Merck Veterinary Manual)

That is why the idea of weekly diclazuril has attracted attention.

It sounds simple: use an established EPM treatment drug at a less frequent schedule during high-risk periods and see whether blood levels stay high enough to suppress the parasite. The key point, though, is that this is still an evolving area. The most important recent study was a pharmacokinetic study, not a clinical prevention trial. It showed that once-weekly labeled-dose diclazuril in healthy adult horses produced plasma concentrations above levels known to inhibit S. neurona in cell culture, but it did not prove that weekly dosing prevents clinical EPM in the field. (PubMed)

Quick Answer

Once-weekly diclazuril is a promising preventive concept for EPM, but it is not a proven standard prevention protocol. Research has shown that giving the FDA-labeled diclazuril dose once every 7 days can achieve plasma concentrations considered inhibitory to Sarcocystis neurona in vitro after repeated dosing. That is encouraging, especially for higher-risk horses, but it is still off-label for prevention and has not yet been proven in large clinical trials to prevent EPM cases in real-world horse populations. (PubMed)

What Is EPM?

EPM is a neurologic disease that affects the brain and spinal cord. It is most commonly associated with Sarcocystis neurona, and horses are infected when they ingest infective sporocysts from opossum fecal contamination of feed, water, or the environment. Horses are considered aberrant or dead-end hosts, and horse-to-horse transmission does not occur. (Merck Veterinary Manual)

The clinical signs vary because the parasite can affect different parts of the central nervous system. Common signs include:

• incoordination

• weakness

• focal muscle atrophy

• asymmetrical neurologic deficits

• cranial nerve signs such as facial asymmetry or swallowing problems

• changes in gait or performance that do not fit a simple orthopedic pattern (Merck Veterinary Manual)

Clinical insight

One reason EPM is so frustrating is that it can look like many other problems. A horse may seem mildly weak behind, vaguely uncoordinated, or just “not right” before the picture becomes clearer. That is why prevention gets so much attention in higher-risk regions.

Why Prevention Has Always Been Difficult

This is the central challenge: exposure is common, disease is not.

Many horses in North America are exposed to S. neurona, but only a small proportion go on to develop clinical EPM. Risk factors reported in guidance and consensus documents include age, stress, transport, surgery, foaling, exercise stress, and environmental exposure where opossums are common. Because not every exposed horse becomes ill, proving that a preventive drug truly prevented disease is much harder than simply measuring whether drug levels were achieved. (AAEP)

That means a lot of prevention research relies on:

• drug concentration studies

• serologic trends

• exposure models

• smaller field observations

Not all of those are equal. Drug levels can be promising without proving real-world disease prevention.

Why Weekly Diclazuril Got Attention

Diclazuril is already FDA-approved for the treatment of EPM. The question researchers asked was whether less frequent dosing might still maintain plasma levels high enough to suppress the organism during periods of risk. (PubMed)

In the 2023 pharmacokinetic study, eight healthy adult horses received the FDA-labeled diclazuril dose of 1 mg/kg orally once every 7 days for five doses. Researchers collected trough and peak blood samples and found that steady-state plasma concentrations known to inhibit S. neurona in vitro were achieved with this once-weekly schedule. According to the study abstract, the weekly approach produced plasma concentrations above the inhibitory threshold used in cell culture work. (PubMed)

That is the important result.

Not “weekly diclazuril is proven prevention.”
But “weekly diclazuril can maintain pharmacologically interesting blood levels.”

What the Study Actually Proved

Here is where precision matters.

The study showed:

• weekly labeled-dose diclazuril can reach and maintain plasma concentrations believed to inhibit S. neurona in vitro

• those concentrations were achieved in healthy adult horses

• the schedule may offer a more practical alternative to daily administration in some settings (PubMed)

The study did not show:

• that weekly dosing prevents all EPM cases

• that it works equally well in every horse

• that it should automatically become standard preventive care

• that it replaces environmental control or diagnostic vigilance (PubMed)

Clinical takeaway

This is a promising pharmacokinetic finding, not a finished prevention answer.

That distinction matters, especially when owners want certainty where the evidence is not there yet.

Is There Any Other Preventive Diclazuril Research?

Yes, and it helps support the general idea that prophylactic diclazuril exposure may influence S. neurona dynamics, though it still does not fully settle the prevention question.

Earlier studies looked at different strategies, including bi-weekly lower-dose administration and daily top-dress pellets in naturally exposed horses or foals. These studies suggested diclazuril exposure could reduce seroprevalence or antibody magnitude in some settings, which is encouraging, but again, serology is not the same thing as preventing clinical neurologic disease. (ScienceDirect)

Why that matters

The body of evidence points toward biologic plausibility.

It does not yet give us a perfect clinical guarantee.

Which Horses Might Be Considered Higher Risk?

Preventive discussions tend to be most relevant in horses with a higher exposure or stress profile.

That may include:

• young performance horses

• horses in heavy travel or show programs

• horses living where opossum exposure is common

• horses on farms with previous EPM history

• horses undergoing periods of transport, surgery, intense training, or other stressors that have been associated with increased risk in observational work (AAEP)

Clinical insight

“Higher risk” does not mean “every horse at a boarding barn.”

This is where a lot of over-treatment starts. Not every horse needs a preventive drug plan just because EPM exists in the region.

Severity Framework: How Strong Is the Case for Preventive Therapy?

Low Priority

• horse is in a low-exposure environment

• no known farm history

• minimal travel

• no particular stress burden

What it usually means:
Environmental management is likely more important than drug prevention.

What to do:
Focus on feed security, wildlife control, and monitoring.

Moderate Priority

• horse lives in an endemic area

• some travel or performance stress

• periodic exposure concerns

What it usually means:
A prevention discussion may be reasonable, especially seasonally.

What to do:
Review exposure risk and decide whether management alone is enough.

Higher Priority

• previous EPM cases on the property

• intense travel or show season

• horse is under substantial stress

• repeated environmental exposure concerns

What it usually means:
This is where off-label preventive diclazuril may become a more serious discussion with your veterinarian.

What to do:
Consider a structured plan, but make sure the owner understands the evidence limits.

Critical misunderstanding to avoid

• horse has vague neurologic signs and diclazuril is started “preventively”

What it usually means:
That is no longer prevention. That is a diagnostic and treatment case.

What to do:
Get the horse examined properly.

When Weekly Diclazuril Makes the Most Sense to Discuss

The strongest argument for weekly diclazuril is not “it is easy.”

It is:

• there is a plausible pharmacokinetic rationale

• the horse is in a meaningful risk window

• daily treatment is less practical

• the owner understands that this is off-label preventive use, not proven absolute protection (PubMed)

Situations where it may come up

• show season in a high-exposure region

• horses moving onto a property with known EPM history

• valuable performance horses under high transport and competition stress

• horses managed on farms where exposure control is imperfect

Situations where it makes less sense

• low-risk horses with no meaningful exposure pressure

• owners wanting a substitute for basic feed and wildlife management

• horses already showing possible neurologic signs

What About Safety?

Diclazuril is generally considered well tolerated in horses when used appropriately, and it is already an approved treatment drug for EPM. That said, weekly preventive use is still off-label, and any ongoing administration plan should be supervised by a veterinarian who knows the horse and the reason for use. (PubMed)

Practical point

A drug being well tolerated does not automatically mean it should be used casually.

The question is not just “can I give it?”
It is “does this horse genuinely justify it?”

What Weekly Diclazuril Does Not Replace

This matters just as much as the drug discussion.

Even if a veterinarian elects to use weekly diclazuril in a higher-risk horse, it does not replace basic EPM prevention measures:

• keep opossums away from feed and water

• store feed in closed containers

• do not leave pet food or grain accessible

• remove attractants such as fallen fruit, garbage, and bird seed around barns

• reduce avoidable stress where possible (Merck Veterinary Manual)

Clinical insight

Drug prevention without environmental control is lazy prevention.

If opossums still have easy access to feed rooms and water sources, the prevention plan is incomplete.

What Should You Do if You Are Considering It?

1. Clarify the goal

Is this true prevention in an asymptomatic horse, or are there already signs that need a workup?

2. Assess actual risk

Look at geography, wildlife exposure, property history, travel, stress, and season.

3. Understand the evidence honestly

Weekly diclazuril is supported by pharmacokinetic data, not definitive field-prevention trials. (PubMed)

4. Build the plan with your veterinarian

Dose, duration, and timing all matter more than internet shortcuts.

5. Keep environmental control in place

Because medication alone is not a complete prevention strategy. (Merck Veterinary Manual)

Common Mistakes Owners Make

Treating a neurologic horse “preventively”

Once clinical signs are present, the case needs diagnostic evaluation, not casual prevention logic.

Thinking blood levels equal guaranteed prevention

They do not. The weekly study showed promising concentrations, not guaranteed field efficacy. (PubMed)

Ignoring opossum control

This is one of the most basic and most important prevention steps. (Merck Veterinary Manual)

Assuming every horse in North America needs preventive medication

Exposure is widespread, but disease is still uncommon relative to exposure. (Equine Disease Communication Center)

Using off-label prevention without veterinary oversight

That is how reasonable ideas turn into poor medicine.

Frequently Asked Questions

Is weekly diclazuril FDA-approved for EPM prevention?

No. Diclazuril is FDA-approved for treatment of EPM, but once-weekly preventive use is off-label. (PubMed)

Does weekly diclazuril definitely prevent EPM?

Not proven. The key published study showed inhibitory plasma concentrations, not definitive prevention of clinical disease. (PubMed)

Which horses are the best candidates to discuss it for?

Usually higher-risk horses in endemic areas, especially during stress-heavy periods such as travel and competition, or on farms with known prior EPM exposure. (AAEP)

Should I use it instead of controlling opossums around feed?

No. Feed and water protection remains a core prevention measure. (Merck Veterinary Manual)

If my horse has subtle neurologic signs, should I start weekly diclazuril?

That should be treated as a diagnostic case first. Do not blur prevention and treatment.

Final Thoughts

Weekly diclazuril is one of the more interesting recent developments in EPM prevention because it gives us something we did not have before: a pharmacokinetic basis for a lower-frequency preventive discussion.

That is useful.

But it is not the same as a proven prevention standard.

The best way to think about it is this:

• promising, not definitive

• selective, not universal

• veterinary-guided, not casual

• supportive of prevention, not a replacement for environmental control

That is the level-headed interpretation the evidence deserves.

If you are trying to decide whether a horse is genuinely high-risk for EPM or whether weekly diclazuril is a reasonable discussion for that situation, ASK A VET™ can help you weigh the evidence, the risk level, and the practical next step.